Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an ...

Quantinuum may not be a household name yet, and it’s not even publicly traded, but it has quickly become one of the most ...

Hiring Dalia Rayes as head of commercial for the global efzofitimod franchise slots another piece of the puzzle into place.

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

After raising an impressive 1.2 billion euros in 2024, European venture capital firm Sofinnova Partners is topping up its ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Sofinnova Partners ("Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, ...

It’s an exciting time for Amgen and we’re glad to discuss the ... early in their life cycle with significant growth ahead, building on $4.5 billion of sales with 17% year-over-year growth ...

According to Gary Russo, Executive Director of Workforce Intelligence at Providence Health & Services, "Bringing together people analytics and skills data will help us innovate in our sourcing and ...

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology ...